Preliminary results for 12 months ended 31 December 2017

Preliminary results for 12 months ended 31 December 2017

20% growth in revenues and a return to adjusted EBITDA profit; continued progress in building a leading global pure-play aesthetics company with significant, long-term growth potential.

Download Results (PDF)

30 April 2018

30 April 2018, Sinclair Pharma plc (AIM: SPH.L), (“Sinclair” or the “Company”) the international aesthetics company, announces its unaudited results for the 12 months ended 31 December 2017.

D

Share this post:

Sinclair Network

At Sinclair we strive to provide the highest standards of training and ongoing support, working in partnership with our physician customers to deliver patients unparalleled clinical results and industry leading safety standards.